The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
New software to deliver faster and more accurate diagnoses in genetic epilepsies is the ambition of a ground-breaking partnership between Congenica, a global provider of clinical genomics interpretation software, and FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, supported by Science Foundation Ireland. The software will be designed to work with electronic health record (EHR) systems, including the Irish electronic health record for Epilepsy, so that the entire diagnostic process, from initial DNA sequencing to determining treatment options, is available to clinicians and patients through their electronic records.
Read the rest of entry »
Oxford, UK: Genomics plc today announced that it has entered into a collaborative deal with Biogen, Inc., the U.S.-based biotech, to work on multiple sclerosis (MS). Biogen is an international leader in drug therapies for MS, with the broadest MS portfolio in the industry.
London, UK: AZD4635 (HTL-1071), a novel adenosine A2A receptor antagonist, reverses adenosine-mediated T-cell suppression and enhances anti-tumour immunity. New preclinical results presented at AACR Annual Meeting
British-Chinese three-way agreement brings together expertise and innovation in development of technologies for computational molecule design.
Oxford, UK & Bagsværd, Denmark - University of Oxford and Novo Nordisk today announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research centre on the premises of the University of Oxford.
Philadelphia, USA - Leading clinical outsourcing services provider, PCI Clinical Services (PCI), has announced a partnership with Suvoda LLC. The agreement will benefit clinical trials, delivering Suvoda’s cutting edge IRT/IWRS technology for subject randomization and trial supply management integrated with PCI’s comprehensive packaging and logistical services for clinical trial supplies.
Oxford, UK - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, today announced that they have partnered with a subsidiary of Aptuit Holdings LLC (Aptuit) for services related to Chronos’ programme targeting the addictive behaviours of binge eating and alcohol use disorders.
29 November 2016: London & Oxford, UK - Orchard Therapeutics, a biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with serious and life-threatening orphan diseases announces today that it has entered into a strategic alliance with Oxford BioMedica plc, a world-leading company in gene and cell therapy.
Under the terms of the collaboration and licence agreement, Oxford BioMedica has granted an exclusive intellectual property licence to Orchard for collaboration programmes, and will provide process development services and manufacture clinical and commercial GMP-grade lentiviral vectors for Orchard. Oxford BioMedica will receive a 1.95% equity stake in Orchard and will be entitled to royalties on future sales of products covered by the collaboration. The process development arrangements include performance-related incentives, through which Oxford BioMedica could receive a further 1.95% equity stake in Orchard.
The agreement is an important milestone for Orcha ...
08 November 2016: Spånga, Sweden & London, UK - Symcel, the company behind the revolutionary cell-based assay tool for real-time cellular bioenergetic measurements, calScreener™, has partnered with TiKa Diagnostics and St. George’s University of London, for the use of its microcalorimetry technology in testing mycobacteria and for antimicrobial peptide (AMP) studies. The rapid detection of antimicrobial resistance is now crucial to maximize efforts in controlling the prevalence and spread of drug resistant Mycobacterium tuberculosis (Mtb). Moreover, the development of novel agents, such as AMPs, able to combat superbugs and interfere with biofilm formation, has become a key necessity.
04 October 2016: Oxford, UK & Cambridge, USA - Sarepta Therapeutics and Summit Therapeutics plc today announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States ('the licensed territory'), to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy ('DMD'). As part of the agreement, Sarepta also obtains an option to license Latin American rights to Summit's utrophin modulator pipeline. Summit retains commercialization rights in all other countries.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.